Top-News

„Special Situation“-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt(Anzeige)

Ein Labormitarbeiter bei der Arbeit (Symbolbild).

Mittwoch, 06.03.2024 08:03 von PR Newswire | Aufrufe: 16

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Ein Labormitarbeiter bei der Arbeit (Symbolbild). © Totojang / iStock / Getty Images Plus / Getty Images

PR Newswire

NORTH CHICAGO, Ill., March 6, 2024

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatologic conditions and aesthetic indications

NORTH CHICAGO, Ill., March 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California. The presented data across AbbVie and Allergan Aesthetics' extensive portfolios reinforce the companies' ongoing commitment to developing transformative medical dermatology and aesthetic treatments to advance and redefine the standard of care for patients.

The oral and poster presentations from AbbVie highlight efficacy, durability and safety data across the company's dermatology portfolio. Notable presentations include:

Efficacy data of RINVOQ^® (upadacitinib) on nighttime itch and sleep disturbance, and minimal disease activity in patients with moderate-to-severe atopic dermatitis
Data evaluating the efficacy of SKYRIZI^® (risankizumab-rzaa) on difficult to treat areas including for the treatment of scalp and nail psoriasis compared to apremilast in adults with moderate psoriasis, and safety and efficacy of SKYRIZI^®(risankizumab-rzaa) in adults with moderate to severe plaque psoriasis with palmoplantar (nonpustular) involvement
Data evaluating changes in tissue-resident memory T cell (Trm) populations after high-induction dosing of SKYRIZI^®(risankizumab-rzaa) in patients with moderate-to-severe plaque psoriasis

AbbVie is also presenting data across a number of underserved dermatologic diseases across new and existing molecules. Key research includes:

Phase 2 efficacy and safety data for lutikizumab (ABT-981), which has a novel mechanism of action, in the treatment of moderate to severe hidradenitis suppurativa being presented for the first time at a medical meeting
Efficacy and safety results of a Phase 2, 52-week study for upadacitinib in the treatment of non-segmental vitiligo
New data on disease and economic burden of alopecia areata in the United States

"AbbVie's commitment to advancing standards of care in dermatology is underscored by the breadth of new research presented at AAD this year," said Andrew Anisfeld, Ph.D., vice president, global medical affairs, Immunology, AbbVie. "We are dedicated to improving patient outcomes and helping to redefine treatment expectations so that all patients may feel free in their own skin."

With a growing pipeline of more than 60 programs in development, Allergan Aesthetics has one of the most robust portfolios for aesthetics innovation in the industry. At AAD the company will spotlight:

Detailed results from two Phase 3 studies of onabotulinumtoxinA (BOTOX^® Cosmetic) for the treatment of platysma prominence, an aesthetically unappealing disruption to the lines and contour of the lower face and neck that can occur as part of the natural aging process. Topline results shared in 2023 demonstrated all primary and secondary endpoints were met for both studies,¹ and if approved, onabotulinumtoxinA will be the first and only neurotoxin for this indication.
Data on the safety and effectiveness of JUVÉDERM^® VOLUMA^® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.² JUVÉDERM^® VOLUMA^® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to thirteen months with optimal treatment.²
Data on a novel cosmetic regimen for mild to moderate facial acne.

"Allergan Aesthetics is focused on creating evidence-based products and technologies that advance aesthetics medicine and address the evolving needs of patients and providers globally," said John Maltman, Ph.D., vice president, global aesthetics medical affairs, Allergan Aesthetics. "With patient safety and optimal outcomes as our main priorities, we are proud to share our learnings and engage with the larger medical community at AAD."

Select AbbVie and Allergan Aesthetics abstracts at AAD 2024 are outlined below. The 2024 AAD Annual Meeting e-Posters are available here and late-breaking sessions are available here.

ARIVA.DE Börsen-Geflüster

Weiter abwärts?

Kurzfristig positionieren in AbbVie Inc.
VM7VL2	Ask: 1,96	Hebel: 20,07
mit starkem Hebel		Zum Produkt
VD0GPK	Ask: 4,58	Hebel: 4,23
mit moderatem Hebel		Zum Produkt

Vontobel

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: VM7VL2,VD0GPK,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.

Kurse

AbbVie Inc.

150,90 €

-0,97%

Abstract Titles	Presentation Details (All Times PT)
ALOPECIA AREATA
Real-World Work Productivity Losses and Associated Costs in Patients with Alopecia Areata in the US	March 9, 2024, 10:55 AM – 11:00 AM ePoster with Oral Presentation Poster Center 1, Upper Level, Sails Pavilion
ATOPIC DERMATITIS
Treatment With Upadacitinib Increases the Achievement of Minimal Disease Activity Among Patients with Moderate-to-Severe Atopic Dermatitis: Results from Phase 3 Studies (Measure Up 1 and Measure Up 2)	March 8, 2024, 9:05 - 9:10 AM ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
Upadacitinib Improves Atopic Dermatitis Related Nighttime Itch and Reduces Sleep Disturbance: Analysis of Time Spent in Response State from the Integrated Phase 3 Measure Up 1 & 2 Clinical Trials	March 8, 2024, 9:20 - 9:25 AM ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
HIDRADENITIS SUPPURATIVA
A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Patients with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	March 9, 2024, 9:30 – 9:40 AM Late-Breaking Presentation Session 1, Room 20BCD
PSORIASIS
High Induction Dosing of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: 52 Week Results from the Phase 2 KNOCKOUT Study	March 9, 2024, 9:10 - 9:20 AM Late-Breaking Presentation Session 1, Room 20BCD
Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study	March 9, 2024, 3:00 - 3:05 PM ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry	March 9, 2024, 3:10 PM - 3:15 PM  ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
Achievement of High NPF Treatment Targets After 52 Weeks in Psoriasis Patients Switching to Risankizumab After Suboptimal Response to Secukinumab or Ixekizumab	March 9, 2024, 3:30 - 3:35 PM ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results from the LIMMitless Open-label Extension Trial For up to 6 Years of Follow-up	March 10, 2024, 2:30 PM - 2:35 PM ePoster with Oral Presentation Poster Center 1, Upper Level, Sails Pavilion
Efficacy and Safety After 52 weeks in Psoriasis Patients Switching to Risankizumab After Suboptimal Response to Secukinumab or Ixekizumab - a Subgroup Analysis	March 10, 2024 , 2:40 PM - 2:45 PM ePoster with Oral Presentation Poster Center 1, Upper Level, Sails Pavilion
Efficacy of Risankizumab for Moderate-to- Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics from the LIMMitless Trial	March 10, 2024, 2:45 PM - 2:50 PM ePoster with Oral Presentation Poster Center 1, Upper Level, Sails Pavilion
Safety and Efficacy of Risankizumab in Adult Patients with Moderate to Severe Plaque Psoriasis with Palmoplantar (nonpustular) Involvement: Change in PASI and PPASI from Phase 3b IMMprint Trial	ePoster
VITILIGO
Efficacy and Safety after 52 weeks of Once- Daily Upadacitinib in Adults with Extensive Non-Segmental Vitiligo (NSV): Final Results from a Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose- Ranging Study	March 9, 2024, 11:30 – 11:40 AM Late-Breaking Presentation Session 1, Room 20BCD
Impact of Achieving FVASI 75 or T-VASI 50 on Patient- and Physician-Reported Outcomes in Patients with Non-Segmental Vitiligo (NSV) Receiving Upadacitinib During a Phase 2 Study	March 9, 2024, 2:20 PM – 2:25 PM ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data from a Phase 2 Upadacitinib Study in Adults with Non-Segmental Vitiligo	March 9, 2024, 2:25 PM – 2:30 PM ePoster with Oral Presentation Poster Center 2, Upper Level, Sails Pavilion
AESTHETICS
Treating Platysma Prominence with OnabotulinumtoxinA: Efficacy and Safety Results from a Phase 3 Multicenter, Randomized, Double-blind, Placebo- Controlled Study	March 8, 2:35 - 2:40 PM ePoster with Oral Presentation Poster Center 1, Upper Level, Sails Pavilion
Evaluating the Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Platysma Prominence: Results from a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study	March 8, 9:45 - 9:50 AM ePoster with Oral Presentation Poster Center 1, Upper Level, Sails Pavilion
Improving Temple Hollowing With a Hyaluronic Acid Injectable Gel, VYC-20L: Results From a Multicenter, Randomized, Evaluator-Blinded, Controlled Pivotal Study	ePoster
Comparable Efficacy and Less Dryness With a Novel Cosmetic Regimen When Compared to a Topical Drug Combination of Adapalene 0.1% and Benzoyl Peroxide 2.5% in Subjects With Mild to Moderate Facial Acne	ePoster

SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI globally.

About RINVOQ^® (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.³ The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

Phase 3 trials of RINVOQ alopecia areata, ankylosing spondylitis, atopic dermatitis, axial spondyloarthritis, Crohn's disease, giant cell arteritis, hidradenitis suppurativa, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE), Takayasu arteritis, ulcerative colitis and vitiligo are ongoing.^4-17

Use of upadacitinib in vitiligo is not approved and its safety and efficacy have not been evaluated by regulatory authorities.

RINVOQ (upadacitinib) U.S. Uses and Important Safety Information³

RINVOQ is a prescription medicine used to treat:

Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.
Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.

It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.

Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.

RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.

It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.

Mehr Nachrichten zur AbbVie Inc. Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.